Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
AZTA 
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.17
1 Year Target Price $40.17
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.19% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.60B USD | Price to earnings Ratio 65.57 | 1Y Target Price 40.17 |
Price to earnings Ratio 65.57 | 1Y Target Price 40.17 | ||
Volume (30-day avg) 7 | Beta 1.29 | 52 Weeks Range 23.91 - 55.63 | Updated Date 12/29/2025 |
52 Weeks Range 23.91 - 55.63 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.39% | Operating Margin (TTM) 1.12% |
Management Effectiveness
Return on Assets (TTM) -0.65% | Return on Equity (TTM) 1.4% |
Valuation
Trailing PE 65.57 | Forward PE 29.07 | Enterprise Value 1308461835 | Price to Sales(TTM) 2.69 |
Enterprise Value 1308461835 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 2.2 | Enterprise Value to EBITDA 33.1 | Shares Outstanding 45989578 | Shares Floating 40592442 |
Shares Outstanding 45989578 | Shares Floating 40592442 | ||
Percent Insiders 0.92 | Percent Institutions 112.07 |
Upturn AI SWOT
Azenta Inc
Company Overview
History and Background
Azenta Inc., formerly Brooks Automation, Inc., was founded in 1978. It has evolved significantly over the decades, primarily in the semiconductor automation and life sciences sectors. A major rebranding to Azenta Inc. occurred in 2022, reflecting a strategic shift towards life sciences. Key milestones include its IPO on NASDAQ and strategic acquisitions that have expanded its capabilities in sample management and life sciences solutions.
Core Business Areas
- Life Sciences Solutions: Provides advanced sample management and automation solutions for the life sciences industry, including sample storage, tracking, and retrieval, as well as laboratory automation equipment and consumables. This segment serves pharmaceutical, biotechnology, and academic research institutions.
- Life Science Services: Offers services such as sample storage, biobanking, and lab outsourcing to support drug discovery, development, and clinical trials. This segment aims to accelerate research and development for its clients.
Leadership and Structure
Azenta Inc. is led by a management team comprising a CEO, CFO, and various division presidents overseeing operations. The company operates as a matrix organization, with a strong emphasis on R&D and customer support across its life sciences focused business units.
Top Products and Market Share
Key Offerings
- Sample Management & Automation Solutions: Includes automated storage and retrieval systems (ASRS) for biological samples, lab automation platforms, and consumables for sample handling. Competitors include Thermo Fisher Scientific (Fisher Scientific, Patheon), Qiagen, and Eppendorf. Specific market share data for individual product lines is proprietary and not publicly disclosed in detail, but Azenta is a significant player in automated sample management.
- Biobanking Services: Provides secure, compliant storage of biological samples for research and clinical purposes. Competitors include public biobanks and specialized private service providers. Azenta aims to capture a growing share of the outsourced biobanking market.
Market Dynamics
Industry Overview
The life sciences industry is experiencing robust growth driven by advancements in biotechnology, personalized medicine, and increasing R&D investments from pharmaceutical companies. The demand for sophisticated sample management and automation solutions is high due to the increasing volume and complexity of biological data and samples.
Positioning
Azenta Inc. is positioning itself as a leader in life sciences automation and sample management. Its competitive advantages lie in its integrated solutions, extensive experience in automation, and commitment to serving the stringent needs of the biopharmaceutical industry. The company leverages its rebranding and strategic focus to differentiate itself from broader life sciences suppliers.
Total Addressable Market (TAM)
The global market for life sciences automation and sample management solutions is estimated to be in the tens of billions of dollars, with significant growth projected. Azenta Inc. is a key contender within this TAM, aiming to increase its market penetration through organic growth and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong expertise in automation and sample management.
- Established relationships within the pharmaceutical and biotech industries.
- Rebranded focus on high-growth life sciences sector.
- Comprehensive portfolio of sample storage and handling solutions.
Weaknesses
- Transition from a diversified industrial automation company to a life sciences focus may present integration challenges.
- Reliance on key customer relationships.
- Competition from larger, more diversified life sciences companies.
Opportunities
- Growing demand for advanced biobanking and sample management services.
- Expansion into emerging markets for life sciences research.
- Strategic partnerships and acquisitions to broaden service offerings.
- Increasing outsourcing trends in pharmaceutical R&D.
Threats
- Economic downturns affecting R&D budgets.
- Intensifying competition from established and new players.
- Regulatory changes impacting the life sciences industry.
- Technological disruption from emerging automation and AI solutions.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Qiagen N.V. (QGEN)
- Agilent Technologies, Inc. (A)
- Danaher Corporation (DHR)
Competitive Landscape
Azenta's advantages include its specialized focus on life sciences sample management and automation, combined with a strong legacy in automation technology. However, it faces formidable competition from much larger, diversified companies like Thermo Fisher Scientific and Danaher, which have broader product portfolios and greater financial resources. Azenta differentiates itself through highly specialized solutions and services tailored to the specific needs of biobanks and research labs.
Major Acquisitions
Dao Health
- Year: 2022
- Acquisition Price (USD millions):
- Strategic Rationale: To enhance Azenta's capabilities in providing integrated solutions for cell and gene therapy development and manufacturing.
Cryoport Inc.
- Year: 2023
- Acquisition Price (USD millions): 1600
- Strategic Rationale: To expand Azenta's cold chain logistics and logistics management services for the life sciences industry, complementing its sample management offerings.
Growth Trajectory and Initiatives
Historical Growth: Historically, Azenta (as Brooks Automation) experienced growth through expansion in automation for various industries, including semiconductor manufacturing. Post-rebranding to Azenta, the focus has shifted, and growth is being driven by the life sciences sector. This shift involves strategic acquisitions and organic growth in its core life sciences solutions and services.
Future Projections: Analyst projections for Azenta Inc. are typically positive, driven by the strong secular growth trends in the life sciences industry. The company is expected to benefit from increased demand for automation in drug discovery, development, and diagnostics. Specific growth percentages depend on analyst consensus and can be found in financial research reports.
Recent Initiatives: Key recent initiatives include the acquisition of companies within the life sciences automation and services space to bolster its capabilities and market reach. The rebranding itself was a major initiative to sharpen its focus. The company is also investing in R&D to develop next-generation automation and sample management technologies.
Summary
Azenta Inc. is strategically focused on the high-growth life sciences market, leveraging its automation expertise for sample management and biobanking. The company's recent rebranding and acquisitions, such as Cryoport, signal a strong commitment to expanding its service offerings and market share. While facing intense competition from larger players, Azenta's specialized solutions and integrated approach position it favorably. Continuous investment in R&D and strategic M&A will be crucial for sustained growth and differentiation in this dynamic industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Azenta Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analyst Reports (for TAM estimates and market share insights)
- Company Press Releases
Disclaimers:
This JSON output is for informational purposes only and should not be considered financial advice. Market share data and TAM estimates are approximate and subject to change. Financial figures are subject to market fluctuations and the most up-to-date information should be obtained from official company filings. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.